ZURICH (Reuters) – Roche said on Monday the U.S. Food and Drug administration granted priority review to its Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults.
“If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients,” Roche said in a statement, adding that more than 1 million people hospitalised with COVID-19 had been treated with Actemra/RoActemra worldwide since the beginning of the pandemic.
(Reporting by Silke Koltrowitz, Editing by Miranda Murray)
